Stockscreener 앱 받기
3.77
9.10%
0.31
전일 마감가:
$3.46
열려 있는:
$3.5
하루 거래량:
2.13M
Relative Volume:
0.53
시가총액:
$508.02M
수익:
-
순이익/손실:
$-217.44M
주가수익비율:
-1.7373
EPS:
-2.17
순현금흐름:
$-205.20M
1주 성능:
-7.25%
1개월 성능:
-13.22%
6개월 성능:
+45.47%
1년 성능:
-12.00%
1일 변동 폭
$3.47
$3.805
1주일 범위
$3.35
$4.138
52주 변동 폭
$1.11
$5.17
Prime Medicine Inc Stock (PRME) Company Profile
명칭
Prime Medicine Inc
전화
617-465-0013
주소
60 FIRST ST., CAMBRIDGE
PRME을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.775 | 625.74M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.40 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.57 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
433.42 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.33 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.25 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-12-10 | 개시 | JMP Securities | Mkt Outperform |
| 2024-05-20 | 개시 | H.C. Wainwright | Buy |
| 2024-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2024-04-22 | 개시 | Chardan Capital Markets | Buy |
| 2024-04-08 | 개시 | TD Cowen | Buy |
| 2024-04-03 | 개시 | Wedbush | Outperform |
| 2024-01-16 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-12-08 | 개시 | Citigroup | Neutral |
| 2023-10-09 | 개시 | BMO Capital Markets | Outperform |
| 2023-07-31 | 개시 | Guggenheim | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2022-11-14 | 개시 | Goldman | Neutral |
| 2022-11-14 | 개시 | JP Morgan | Overweight |
| 2022-11-14 | 개시 | Jefferies | Buy |
| 2022-11-14 | 개시 | Morgan Stanley | Equal-Weight |
모두보기
Prime Medicine Inc 주식(PRME)의 최신 뉴스
Guggenheim cuts Prime Medicine stock price target to $5 from $18 - Investing.com Canada
Does Prime Medicine Inc. stock reflect fundamentalsJuly 2025 Earnings & Expert Curated Trade Ideas - thegnnews.com
Is Prime Medicine Inc. exposed to political riskUltra High Profit Potential - newsyoung.net
Is Prime Medicine Inc. forming higher highs and higher lowsMulti-Bagger Picks in Progress - thegnnews.com
H.C. Wainwright Maintains Prime Medicine(PRME.US) With Hold Rating - 富途牛牛
Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00 - Defense World
What makes Prime Medicine Inc. stock price move sharplyHigh Return Trade Roadmap with Setup Filters - Newser
Prime Medicine Inc. stock trendline breakdownFree Consistent Income Focused Trade List - Newser
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates - MSN
How high can Prime Medicine Inc. stock goFree Community Verified Stock Suggestions - Newser
Prime Medicine stock price target lowered to $10 at Chardan on cash update - Investing.com Canada
Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position - TipRanks
Prime Medicine Inc. stock retracement – recovery analysisFree Stock Market Entry Timing Signals - Newser
Prime Medicine Reports Q2 2025 Results and Strategic Updates - TipRanks
Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire
PRME Revenue Misses by 73% - AOL.com
Prime Medicine reports Q2 EPS (41c), consensus (34c) - TipRanks
Prime Medicine, Inc. SEC 10-Q Report - TradingView
Prime Medicine, Inc. Q2 operating expenses USD 54.492 million - MarketScreener
Alphabet Discloses $4.95 Million Equity Purchase in Prime Medicine via GV - TechGraph
Major Investment Alert: Prime Medicine, Inc. Sees Significant Share Purchase! - TipRanks
Prime Medicine (NYSE:PRME) Shares Gap Up Following Insider Buying Activity - Defense World
Why Prime Medicine Inc. stock attracts strong analyst attentionPrice Action Summary and Entry Strategy Guide - Newser
Prime Medicine Holds Special Stockholder Meeting - TipRanks
Bank of New York Mellon Corp Acquires 26,478 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Head to Head Comparison: Prime Medicine (NYSE:PRME) vs. Calidi Biotherapeutics (NYSE:CLDI) - Defense World
Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity - Defense World
Firm Advises Prime Medicine on IP Matters Related to $144 Million Public Offering - Wilson Sonsini
Prime Medicine Surges 8.5% Amid KDJ Golden Cross Signal and Biotech Sector Rally - AInvest
Prime Medicine (PRME.O) Sees Sharp Intraday Surge—What’s Driving the Move? - AInvest
Why is Prime Medicine Inc. stock attracting strong analyst attentionAchieve rapid capital gains with smart investing - Jammu Links News
What are the latest earnings results for Prime Medicine Inc.Free Consultation - Jammu Links News
What institutional investors are buying Prime Medicine Inc. stockGet insider insights into market trends - Jammu Links News
What drives Prime Medicine Inc. stock priceAchieve rapid financial growth with smart picks - Jammu Links News
What are Prime Medicine Inc. company’s key revenue driversAchieve breakthrough performance in the market - Jammu Links News
When is Prime Medicine Inc. stock expected to show significant growthUnlock your portfolio’s hidden potential - Jammu Links News
What analysts say about Prime Medicine Inc. stockStay informed with daily expert analysis - Jammu Links News
Is Prime Medicine Inc. a growth stock or a value stockInvest confidently with advanced analysis tools - Jammu Links News
What is the risk reward ratio of investing in Prime Medicine Inc. stockUnlock powerful market trend analysis - Jammu Links News
Is Prime Medicine Inc. stock overvalued or undervaluedInvest smarter with daily market updates - Jammu Links News
Major Stakeholders Make Bold Moves in Prime Medicine Stock! - TipRanks
Arch venture fund XII buys Prime Medicine shares worth $9.99m - Investing.com Nigeria
Arch venture fund XII buys Prime Medicine shares worth $9.99m By Investing.com - Investing.com South Africa
Prime Medicine shares rise 1.98% after-hours following the closing of a $144.2 million stock offering. - AInvest
Prime Medicine's $144.2M Equity Raise and Strategic Implications - AInvest
Prime Medicine Closes $144.2 Million Stock Offering - MarketScreener
Prime Medicine's Strategic Capital Raise: A Catalyst for Gene Editing Innovation and Shareholder Value - AInvest
Prime Medicine Announces Closing of Public Offering and - GlobeNewswire
Prime Medicine Secures $144M Funding Boost with Strategic Cystic Fibrosis Foundation Investment - Stock Titan
Prime Medicine stock falls after pricing public offering By Investing.com - Investing.com Australia
JonesTrading Maintains a Buy on Prime Medicine (PRME) - Insider Monkey
Prime Medicine Inc (PRME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Prime Medicine Inc 주식 (PRME) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| NELSEN ROBERT | Director |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners XII, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| ARCH Venture Partners X, LLC | 10% Owner |
Aug 01 '25 |
Buy |
3.30 |
3,030,300 |
9,999,990 |
6,230,300 |
| Liu David R. | 10% Owner |
Jun 30 '25 |
Buy |
2.52 |
21,000 |
52,830 |
20,240,945 |
| Liu David R. | 10% Owner |
Jun 23 '25 |
Buy |
2.16 |
21,000 |
45,402 |
20,219,945 |
| Liu David R. | 10% Owner |
Jun 16 '25 |
Buy |
1.49 |
21,000 |
31,196 |
20,198,945 |
| Liu David R. | 10% Owner |
Jun 11 '25 |
Buy |
1.60 |
21,000 |
33,590 |
20,177,945 |
| Brudnick Richard | Chief Business Officer |
May 20 '25 |
Buy |
1.19 |
20,000 |
23,790 |
20,000 |
| LEE ANN L. | Chief Technical Officer |
May 21 '25 |
Buy |
1.13 |
100,000 |
113,000 |
100,000 |
| Reine Allan | Chief Executive Officer |
May 21 '25 |
Buy |
1.18 |
125,000 |
147,150 |
125,000 |
0.57%
0.03%
자본화:
|
볼륨(24시간):